ProShare Advisors LLC Purchases 10,379 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

ProShare Advisors LLC grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 44.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,699 shares of the biopharmaceutical company’s stock after acquiring an additional 10,379 shares during the period. ProShare Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $703,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $27,000. Farther Finance Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $65,000. KBC Group NV increased its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares during the period. Finally, Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $104,000. 79.22% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 351,879 shares of company stock worth $8,214,815 over the last 90 days. 10.40% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $24.49 on Friday. The stock has a market cap of $2.99 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The firm’s 50-day simple moving average is $23.53 and its two-hundred day simple moving average is $22.56.

Analysts Set New Price Targets

CPRX has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird upped their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.